- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05029531
Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021)
August 26, 2021 updated by: Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Prospective Single Group Study Combined Immuno-hemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021)
The innovation of this protocol is the risk-adapted choice of therapy and the use of a combination of chemotherapy with immunotherapy and hematopoietic stem cell transplantation for patients with risk factors. we have proposed a two-stage stratification into risk groups:
Initially:
- Standard risk: patients with no rearrangement of the KMT2A gene.
- Intermediate risk: patients with rearrangement of the KMT2A gene without damage to the central nervous system.
- High risk: patients with rearrangement of the KMT2A gene with lesions of the central nervous system.
According to the results of induction therapy:
- The high-risk group includes patients from the standard risk group with an MRD level of more than 0.1% after the induction course and from the intermediate risk group with MRD-positive (PCR) after HR1 block.
- The allocation of children in the first year of life without the rearranged KMT2A gene into a separate group seems to be logical, since the prognosis in this group is better than in children with the rearranged KMT2A gene. In this protocol, non-intensive therapy with consolidations and maintenance therapy remains for those who achieve a low MRD level (less than 0.1%) after a course of induction. The rest of the patients move into a high-risk group: they receive blinatumomab and HSCT.
- The concept of therapy for patients at intermediate risk is based on the rate at which MRD-negativity is achieved: standard consolidation and maintenance therapy for those who became MRD-negative at the end of induction, "block" chemotherapy for those who were positive at the end of induction, but achieved negativity after HR1 block, blinatumomab with HSCT for those who have preserved the MRD after the HR1 block.
- For high-risk patients, a combination of immunotherapy (blinatumomab - a bispecific CD3 / CD19 T-cell activator) and HSCT in the first remission was chosen.
Study Overview
Status
Not yet recruiting
Detailed Description
- Standard risk group:
- Induction of remission: 36 days of dexamethasone, 5 weekly injections of vincristine, 2 injections of daunorubicin on days 8 and 22, a single injection of pegelated asparaginase on days 5-7 and 6 weekly intrathecal injections of three drugs (methotrexate, cyamethosar and dexamethason ).
- Further therapy in this therapeutic group depends on the status of remission, the level of MRD on the 36th day of therapy.
- MRD-negative patients receive consolidation therapy in the amount of 3 consolidations (6-mercaptopurine, methotrexate, peg-asparaginase, daunorubicin) with re-induction courses (dexamethasone, vincristine) and maintenance therapy (6-mercaptopurine, methotrexate).
- MRD-positive patients receive a course of blinatumomab and HSCT.
- Intermediate risk group:
- Induction of remission: 36 days of dexamethasone, 5 weekly injections of vincristine, 2 injections of daunorubicin on days 8 and 22, a single injection of pegelated asparaginase on days 5-7, 6 weekly intrathecal injections of three drugs (methotrexate, cyamethosar, dexamethasone).
- Further therapy in this therapeutic group depends on the status of remission on the 36th day of therapy.
- Patients who have achieved molecular remission receive consolidation therapy in the amount of 3 consolidations with re-induction courses and maintenance therapy.
- Patients who have not achieved molecular remission receive HR1 block. Further therapy depends on the remission status after HR1 block. Patients who have not achieved molecular remission receive a course of blinatumomab and HSCT, patients who have achieved molecular remission, two more blocks HR2 and HR3, protocol II and maintenance therapy.
- High risk group:
- Induction of remission: 36 days of dexamethasone, 5 weekly injections of vincristine, 2 injections of daunorubicin on days 8 and 22, a single injection of pegelated asparaginase on days 5-7, 6 weekly intrathecal injections of three drugs (methotrexate, cyamethosar, dexamethasone).
- Further therapy in this therapeutic group does not depend on the status of remission on the 36th day of therapy.
- All patients receive HR1 block, blinatumomab course and HSCT (subject to morphological remission).
Study Type
Interventional
Enrollment (Anticipated)
80
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Natalya f Myakova, PD
- Phone Number: +79035083576
- Email: Natalya.Myakova@fccho-moscow.ru
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 day to 1 year (CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age at diagnosis at 1 to 365 days of life.
- The start of induction therapy within a time interval of study recruitment phase.
- The diagnosis of ALL is to be proved by the morphological, cytochemical, and immunological analysis of tumor cells in bone marrow (see "Diagnostics"). Patients with B-cell (Burkitt) ALL are excluded.
- Informed consent of the patient parents (guardians) to be treated in one of the clinics included in this study.
Exclusion Criteria:
- The disease is a relapse of previously misdiagnosed and, therefore, inadequately treated ALL;
- There is severe concomitant disease, which significantly impedes chemotherapy protocol (such as multiple malformations, heart diseases, metabolic disorders, etc.);
- There is a lack of important data needed for the exact adherence to the cytostatic therapy according to a specific chemotherapy protocol (differential diagnosis of ALL-AML (acute myeloid leukemia) is not possible, stratification according to therapeutic group is not possible);
- The patient was treated before for a long time with cytotoxic drugs;
- There were treatment deviations not covered by the protocol and/or not due to side effects of treatment and/or complications of the disease
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: intervention/treatment
|
two-stage stratification into risk groups: Initially and According to the results of induction therapy MRD-positive patients receive a course of blinatumomab and HSCT.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
event free survival
Time Frame: 4 years after the start of therapy
|
4 years after the start of therapy
|
overal survival
Time Frame: 4 years after the start of therapy
|
4 years after the start of therapy
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
risk of relapse
Time Frame: 3 years after the start of therapy
|
3 years after the start of therapy
|
frequency of achieving MRD-negative remission
Time Frame: after a course of induction up to 1 week
|
after a course of induction up to 1 week
|
frequency of achieving MRD-negative remission
Time Frame: after a course of consolidation up to 1 week
|
after a course of consolidation up to 1 week
|
mortality associated with HSCT
Time Frame: 2 years post HSCT
|
2 years post HSCT
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
September 1, 2021
Primary Completion (ANTICIPATED)
July 1, 2029
Study Completion (ANTICIPATED)
July 1, 2030
Study Registration Dates
First Submitted
August 26, 2021
First Submitted That Met QC Criteria
August 26, 2021
First Posted (ACTUAL)
August 31, 2021
Study Record Updates
Last Update Posted (ACTUAL)
August 31, 2021
Last Update Submitted That Met QC Criteria
August 26, 2021
Last Verified
August 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCHPOI-2021-03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Lymphoblastic Leukemia, Pediatric
-
Emory UniversityTerminatedPediatric Acute Myeloblastic Leukemia, Relapsed | Pediatric Acute Lymphoblastic Leukemia, RelapsedUnited States
-
Indiana UniversityNational Institute of Nursing Research (NINR); Ann & Robert H Lurie Children... and other collaboratorsRecruitingAcute Lymphoblastic Leukemia, Pediatric | Pediatric CancerUnited States
-
MedImmune LLCTerminatedB-Cell Pediatric ALLUnited States, Australia, France, Spain, Canada, Netherlands, United Kingdom, Italy
-
University of BirminghamAstraZeneca; Cancer Research UKTerminatedAcute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, Adult | Acute Lymphoblastic Leukemia RecurrentUnited Kingdom, Denmark, Netherlands
-
University College, LondonNot yet recruitingAcute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, Adult | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved Remission
-
Tanja Andrea GruberRecruitingAcute Lymphoblastic Leukemia, Pediatric | Refractory Acute Lymphoblastic Leukemia | Relapsed Acute Lymphoblastic LeukemiaUnited States
-
Beijing Boren HospitalRecruitingAcute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic LeukemiaChina
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinRecruitingAcute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia Recurrent | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved RemissionUnited States
-
Children's Mercy Hospital Kansas CityCompletedRefractory Acute Myeloid Leukemia | Refractory Acute Lymphoblastic Leukemia | Relapsed Pediatric AML | Relapsed Pediatric ALLUnited States
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI)RecruitingLeukemia | Acute Lymphoblastic Leukemia | Pediatric Acute Lymphoblastic LeukemiaUnited States
Clinical Trials on the risk-adapted choice of therapy and the use of a combination of chemotherapy with immunotherapy and hematopoietic stem cell transplantation for patients with risk factors.
-
Memorial Sloan Kettering Cancer CenterTerminatedFibrillation | Post-Operative Cancer Patients Experiencing AtrialUnited States
-
Norwegian Institute of Public HealthUniversity of Oslo; Oslo University Hospital; Oslo MunicipalityActive, not recruitingHip Fractures | Fall Injury
-
Johannes Kepler University of LinzRecruiting
-
Hospital JP GarrahanHospital Pereyra Rosell, Montevideo, UruguayRecruitingPediatric Hodgkin's DiseaseArgentina
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...UnknownTesticular Germ Cell Tumor | Brain and Central Nervous System Tumors | Extragonadal Germ Cell TumorItaly
-
Duke UniversityNational Cancer Institute (NCI)Withdrawn
-
University Hospital, BordeauxRecruiting
-
BonusBio Group LtdCompletedBone Void in the Maxillofacial AreaIsrael
-
City of Hope Medical CenterNational Cancer Institute (NCI)Completed
-
Central Hospital, Nancy, FranceRecruitingCardiovascular Diseases | Risk Factors | Nutrition | Cohort Studies | GenotypeFrance